Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of JNJ-61803534 in Healthy Participants
NCT03139500Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-61803534 in psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants With Adverse Events (AEs) as a Measure of Safety up to 14 weeks. Started May 2017; status: terminated.
02
Drugs
JNJ-61803534
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03139500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139500.